Abstract
Sjogren’s Disease (SjD), like many autoimmune diseases, shows a strong female-to-male sex bias, raising the possibility of a hormone-mediated mechanism. However, specific hormonal drivers and the underlying mechanisms remain unclear. In this study, we analyze a electronic health record dataset containing >100,000 SjD patients, allowing for a comprehensive statistical investigation into sex bias and serum hormone levels associated with SjD susceptibility. Focusing on testosterone, estradiol, and sex hormone-binding globulin (SHBG), our analysis reveals an age-dependent trend in SjD’s sex bias, with a substantially reduced female bias observed in pediatric cases. This finding, alongside statistical modeling, suggests that testosterone or estradiol may influence the sex disparity in SjD prevalence, with distinct effects at different life stages. Specifically, we observe a higher percentage of male SjD patients in early childhood (30.06%, [CI: 26.16-34.11]), declining sharply in late pubescence into adulthood (9.85% [CI: 9.51–10.16]), followed by a secondary steady increase in male prevalence among older adults (13.50% [CI: 13.25-13.76]). Our models indicate that these shifts in sex bias align with typical age-related hormonal changes rather than abnormal levels, suggesting that natural hormone fluctuations may play a significant role in modulating disease susceptibility. This research not only refines our understanding of SjD but also underscores the importance of hormone-level monitoring in future SjD studies and potential therapeutic strategies. Advanced studies are required to further clarify whether testosterone or estradiol is the primary mediator of these trends, promising new insights into hormone-linked pathways and autoimmune disease pathogenesis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of Utah, Institutional Review Board gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available through request to TriNetX, LLC.
